Saturday 17 October 2026
Export INAB’s income statement to Excel — free account
IN8bio, Inc.
INAB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 79.8% and free cash flow fell 1.30%, each against the same quarter a year earlier.
1.11
0.08
−6.72%
Follow INAB
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 12.11 | 1.18 | 7.05 | 17.28 | 3.82 | 4.57 | 4.08 | 8.82 |
Net Debt/EBITDA |
— | 2.62 | 0.12 | 2.10 | 2.65 | 0.63 | 0.75 | 0.39 | 1.56 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.83% | 0.64% | 2.45% | 1.56% | 1.41% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.01 | 0.01 | 0.04 | 0.02 | 0.02 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.10 | 0.81 | 0.69 | 0.92 | 0.85 | 0.78 | 0.79 | 0.65 |
Capex/Depreciation |
— | 0.00 | 3.71 | 0.00 | (0.39) | (3.36) | (0.24) | (0.07) | 0.00 |
Interest Coverage |
— | (286.29) | — | — | — | — | — | — | — |
| — | 37.20% | 87.64% | 80.09% | (135.65%) | (93.64%) | (125.90%) | (154.44%) | (92.49%) | |
| — | (85.12%) | (168.31%) | (93.83%) | (46.42%) | (75.79%) | (89.91%) | (111.38%) | (73.05%) | |
ROIC |
— | 0.00% | 0.00% | (1,067.49%) | (639.98%) | (332.51%) | (453.60%) | (524.69%) | (2,663.76%) |
Return on Tangible Assets |
— | (46.05%) | (1,515.90%) | (65.62%) | (39.80%) | (137.06%) | (131.92%) | (246.39%) | (73.15%) |
Average Days of Receivables |
— | 0.00 | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.14) | (41.85) | (62.63) | (41.62) | (39.85) | (24.07) | (13.63) | (2.91) |
Cash per Share |
— | 0.26 | 5.74 | 157.98 | 111.51 | 26.04 | 21.40 | 6.23 | 6.19 |
Shareholders Equity per Share |
— | 0.24 | (3.26) | 160.85 | 115.01 | 32.56 | 25.07 | 8.11 | 6.30 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.24 | (3.26) | 160.85 | 115.01 | 32.56 | 25.07 | 8.11 | 6.30 |
Free Cash Flow |
— | (2.77) | (4.44) | (7.13) | (13.82) | (27.83) | (23.94) | (24.34) | (12.71) |
Working Capital |
— | 4.65 | 0.12 | 15.57 | 36.72 | 16.41 | 19.23 | 9.50 | 24.72 |
Capital Expenditures |
— | (0.76) | 0.36 | — | (0.31) | (3.70) | (0.60) | (0.19) | — |
Net Current Asset Value |
— | 3.82 | (0.71) | 15.56 | 34.94 | 11.93 | 15.85 | 6.11 | 23.16 |
| Other line items | |||||||||
Quick Ratio |
— | 11.98 | 0.94 | 7.00 | 16.41 | 3.12 | 3.95 | 3.61 | 8.57 |
Depreciation/Fixed assets |
— | 0.12 | 0.35 | 0.47 | 8.12 | 0.25 | 0.71 | 0.93 | 1.35 |
Cash ROIC |
— | (28.73%) | (1,683.71%) | (19.55%) | (18.31%) | (66.69%) | (51.22%) | (93.99%) | (23.26%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.14) | (45.21) | (62.63) | (40.69) | (34.55) | (23.47) | (13.53) | (2.91) |
Capex per Share |
— | 0.00 | 3.35 | 0.00 | (0.93) | (5.31) | (0.60) | (0.10) | 0.00 |
Average Payables |
— | — | 0.59 | 0.59 | 0.51 | 1.24 | 1.51 | 0.66 | 0.35 |
Average Assets |
— | 2.95 | 3.51 | 11.02 | 31.57 | 37.63 | 33.37 | 27.33 | 26.61 |
Average Common Equity |
— | (6.75) | (6.75) | (12.91) | 10.80 | 30.46 | 23.83 | 19.71 | 21.02 |
Capex to Sales |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates